Systemic lupus erythematosus diagnosis and management
暂无分享,去创建一个
[1] Y. Levy,et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide , 2009, Annals of the rheumatic diseases.
[2] D. Gladman,et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. , 2012, Seminars in arthritis and rheumatism.
[3] J. Yazdany,et al. Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus , 2015, Arthritis care & research.
[4] D. Gladman,et al. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. , 2008, Arthritis and rheumatism.
[5] B. Parker,et al. SLE and metabolic syndrome , 2013, Lupus.
[6] G. Hughes,et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. , 2003, Rheumatology.
[7] F. Houssiau,et al. Thirty years of cyclophosphamide: assessing the evidence , 2007, Lupus.
[8] R. Tattersall. The MAGICC and practical approach to rheumatology transition. , 2012, British journal of hospital medicine.
[9] R. Sakthiswary,et al. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy , 2014, Lupus.
[10] A D GUNN,et al. Case of Anaphylaxis after Anaesthesia , 1943, British medical journal.
[11] Hui Luo,et al. Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus , 2015, Genom. Proteom. Bioinform..
[12] K. Kalunian,et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study , 2016, Annals of the rheumatic diseases.
[13] C. Gordon,et al. Malignancies in systemic lupus erythematosus , 2013, Systemic Lupus Erythematosus.
[14] D. Gladman,et al. Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome , 2010, The Journal of Rheumatology.
[15] M. Petri,et al. Unmet medical needs in systemic lupus erythematosus , 2012, Arthritis Research & Therapy.
[16] D. Furst,et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis , 2010, Arthritis care & research.
[17] E. Ginzler,et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. , 1975, Arthritis and rheumatism.
[18] L. Trupin,et al. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. , 2015, Seminars in arthritis and rheumatism.
[19] Anisur Rahman,et al. Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review , 2013, Arthritis care & research.
[20] D. Isenberg,et al. DNA-damaging autoantibodies and cancer: the lupus butterfly theory , 2016, Nature Reviews Rheumatology.
[21] M. Hudson,et al. Treatment Algorithms in Systemic Lupus Erythematosus , 2015, Arthritis care & research.
[22] G. Tsokos,et al. Systemic lupus erythematosus. , 2011, The New England journal of medicine.
[23] J. Piette,et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. , 2002, The Journal of rheumatology.
[24] E. Morand,et al. Vitamin D and systemic lupus erythematosus: continued evolution , 2015, International journal of rheumatic diseases.
[25] D. Isenberg,et al. How to monitor SLE in routine clinical practice , 2005, Annals of the rheumatic diseases.
[26] J. Branco,et al. Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real‐Life, International Systemic Lupus Erythematosus Cohort , 2015, Arthritis care & research.
[27] R. Glassock,et al. Renal disease : classification and atlas , 1987 .
[28] J. Reveille,et al. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort , 2010, Arthritis care & research.
[29] M. Klein-Gitelman,et al. International Consensus for Provisions of Quality‐Driven Care in Childhood‐Onset Systemic Lupus Erythematosus , 2013, Arthritis care & research.
[30] Lee Hebert,et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.
[31] C. Gordon,et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. , 2011, Autoimmunity reviews.
[32] T. Luger,et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus , 2010, The British journal of dermatology.
[33] D. Gladman,et al. Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus , 2014, The Journal of Rheumatology.
[34] L. Punzi,et al. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. , 2012, Clinical and experimental rheumatology.
[35] J. Buyon,et al. The clinical spectrum of autoimmune congenital heart block , 2015, Nature Reviews Rheumatology.
[36] D. Gladman,et al. Clinically active serologically quiescent systemic lupus erythematosus. , 2003, The Journal of rheumatology.
[37] S. Grando,et al. Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study , 2015, Dermatology reports.
[38] What investigations are needed to optimally monitor for malignancies in SLE? , 2015, Lupus.
[39] D. Isenberg,et al. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design , 2013, Arthritis Research & Therapy.
[40] S. Ozen,et al. Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. , 2014, Clinical and experimental rheumatology.
[41] K. Kalunian,et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. , 1994, The Journal of rheumatology.
[42] Jinoos Yazdany,et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis , 2012, Arthritis care & research.
[43] M. Marmor,et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.
[44] Gerald McGwin,et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.
[45] D. Gladman,et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period , 2012, Arthritis care & research.
[46] M. Son,et al. Disease activity and transition outcomes in a childhood-onset systemic lupus erythematosus cohort , 2016, Lupus.
[47] M. Petri,et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials , 2013, Annals of the rheumatic diseases.
[48] I. Bruce,et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force , 2014, Annals of the rheumatic diseases.
[49] J. Stockman. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis , 2013 .
[50] K. Legault,et al. Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous , 2016, BMJ Case Reports.
[51] A. Kuhn,et al. The classification and diagnosis of cutaneous lupus erythematosus. , 2014, Journal of autoimmunity.
[52] N. Wulffraat,et al. HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know , 2016, Pediatric Rheumatology.
[53] M. Petri,et al. Managing lupus patients during pregnancy. , 2013, Best practice & research. Clinical rheumatology.
[54] Y. Chan,et al. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore , 2008, European Journal of Clinical Pharmacology.
[55] J. Callen. Management of antimalarial-refractory cutaneous lupus erythematosus , 1997, Lupus.
[56] K. Kirou,et al. What Causes Lupus Flares? , 2016, Current Rheumatology Reports.
[57] A. Robinson,et al. Systemic lupus erythematosus, bone health, and osteoporosis , 2015, Current opinion in endocrinology, diabetes, and obesity.
[58] BJ Parker,et al. High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus , 2007, Lupus.
[59] J. Harley,et al. Evidence of Dynamically Dysregulated Gene Expression Pathways in Hyperresponsive B Cells from African American Lupus Patients , 2013, PloS one.
[60] E. Yelin,et al. A quality indicator set for systemic lupus erythematosus. , 2009, Arthritis and rheumatism.
[61] L. Lennard. Implementation of TPMT testing. , 2014, British journal of clinical pharmacology.
[62] G. Baehr,et al. Use of cortisone and adrenocorticotropic hormone in acute disseminated lupus erythematosus. , 1950, A.M.A. archives of internal medicine.
[63] Mimi Y. Kim,et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. , 2005, The New England journal of medicine.
[64] S. Bernatsky,et al. Malignancies in systemic lupus erythematosus: a 2015 update , 2015, Current opinion in rheumatology.
[65] J. Stevenson,et al. Bisphosphonate drug holidays – when, why and for how long? , 2015, Climacteric : the journal of the International Menopause Society.
[66] L. Lightstone. Minimising steroids in lupus nephritis – will B cell depletion pave the way? , 2013, Lupus.
[67] T. Chan. Treatment of severe lupus nephritis: the new horizon , 2015, Nature Reviews Nephrology.
[68] P H Plotz,et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.
[69] R. Fischer-Betz,et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.
[70] J. Gómez-Reino,et al. Adipokines, Metabolic Syndrome and Rheumatic Diseases , 2014, Journal of immunology research.
[71] Y. Levy,et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. , 2004, Arthritis and rheumatism.
[72] M. Hochberg,et al. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.
[73] M. Haust,et al. Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). , 2009, Autoimmunity reviews.
[74] M. McClung. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required? , 2013, Clinical obstetrics and gynecology.
[75] D. Painter. Renal Disease: Classification and Atlas of Glomerular Diseases , 1996 .
[76] E. Logigian,et al. Neurological manifestations of primary Sjogren's syndrome. , 2010, Current opinion in neurology.
[77] L. Magder,et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis , 2006, Lupus.
[78] J. Yazdany,et al. Systematic review of the literature informing the systemic lupus erythematosus indicators project: Reproductive health care quality indicators , 2011, Arthritis care & research.
[79] W. Mccune,et al. Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity? , 2015, Current opinion in rheumatology.
[80] C. Ramos,et al. Obesity and Cytokines in Childhood-Onset Systemic Lupus Erythematosus , 2014, Journal of immunology research.
[81] J. Reveille,et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. , 2009, Arthritis and rheumatism.
[82] Q. Nguyen,et al. Faculty Opinions recommendation of Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2011 .
[83] J. Sánchez-Guerrero,et al. Menopause hormonal therapy in women with systemic lupus erythematosus. , 2007, Arthritis and rheumatism.
[84] A. Reiff,et al. Transition of Care and Health‐Related Outcomes in Pediatric‐Onset Systemic Lupus Erythematosus , 2015, Arthritis care & research.
[85] B. Diamond,et al. Pulse steroids: how much is enough? , 2006, Autoimmunity reviews.
[86] E. Chakravarty,et al. Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity , 2013, The Journal of Rheumatology.
[87] G. Ruiz-Irastorza,et al. Predictors of major infections in systemic lupus erythematosus , 2009, Arthritis research & therapy.
[88] J. Ahearn,et al. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.
[89] I. Bruce,et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort , 2014, Annals of the rheumatic diseases.
[90] B. Rovin,et al. Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study , 2014, Arthritis & rheumatology.
[91] G. Hughes. What causes lupus , 2009 .
[92] J. Ioannidis,et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs , 2010, Annals of the rheumatic diseases.
[93] A. Aggarwal,et al. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? , 2015, International journal of rheumatic diseases.
[94] E. Morand,et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) , 2015, Annals of the rheumatic diseases.
[95] I. Bruce,et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort , 2016, Lupus Science & Medicine.
[96] J. Piette,et al. Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. , 2002, Seminars in arthritis and rheumatism.
[97] S. Pantovic,et al. Late-onset systemic lupus erythematosus: clinical features, course, and prognosis , 2013, Clinical Rheumatology.
[98] A. Rojas-Villarraga,et al. Safety of Hormonal Replacement Therapy and Oral Contraceptives in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis , 2014, PloS one.
[99] Christie M. Bartels,et al. A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. , 2016, Seminars in arthritis and rheumatism.
[100] K. Yancey,et al. Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. , 2014, Journal of dermatological science.
[101] M. Petri,et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. , 2013, Arthritis and rheumatism.
[102] M. Petri,et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.
[103] C. Chambers,et al. State of the art: Reproduction and pregnancy in rheumatic diseases. , 2015, Autoimmunity reviews.
[104] J F Fries,et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.
[105] J. Reveille,et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) , 2007, Annals of the rheumatic diseases.
[106] D. Gladman,et al. Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review , 2016, The Journal of Rheumatology.
[107] Virginia Pascual,et al. Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.
[108] J. James,et al. Preclinical lupus , 2015, Current opinion in rheumatology.
[109] H. Brunner,et al. Update on differences between childhood-onset and adult-onset systemic lupus erythematosus , 2013, Arthritis Research & Therapy.
[110] J. Craig,et al. Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines , 2015, Arthritis care & research.
[111] I. Bruce,et al. Prolonged remission in systemic lupus erythematosus. , 2005, The Journal of rheumatology.
[112] G. Alarcón,et al. Incomplete Systemic Lupus Erythematosus: Early Diagnosis or Overdiagnosis? , 2016, Arthritis care & research.
[113] R. Sontheimer,et al. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. , 1981, Journal of the American Academy of Dermatology.
[114] J. Pouchot,et al. Adherence to treatment in systemic lupus erythematosus patients. , 2013, Best practice & research. Clinical rheumatology.
[115] M. Maxwell,et al. Azathioprine treatment of immunological renal disease. , 1967, JAMA.
[116] K. Kalunian. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells? , 2016, Lupus.
[117] S. West,et al. Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. , 2004, Arthritis and rheumatism.
[118] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[119] M. Aringer,et al. Therapeutic blockade of TNF in patients with SLE-promising or crazy? , 2012, Autoimmunity reviews.
[120] J. McDonagh,et al. Adolescent rheumatology transition care in the UK. , 2012, Pediatric annals.
[121] D. Solomon,et al. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals , 2012, Arthritis Research & Therapy.
[122] N. Senn,et al. Development of a Comprehensive Approach for the Early Diagnosis of Geriatric Syndromes in General Practice , 2015, Front. Med..
[123] B. Fessler,et al. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. , 2000, Chest.
[124] K. Schreiber. Pregnancies in women with systemic lupus erythematosus and antiphospholipid antibodies , 2016, Lupus.
[125] K. Costenbader,et al. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. , 2013, Seminars in arthritis and rheumatism.
[126] G. Valesini,et al. Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up Study , 2012, PloS one.
[127] C. Cooper,et al. Serum 25‐Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[128] E. Bonfá,et al. Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials , 2015, Arthritis care & research.
[129] J. Callen. Management of "refractory" skin disease in patients with lupus erythematosus. , 2005, Best practice & research. Clinical rheumatology.
[130] J. Singh,et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination , 2016, Arthritis & rheumatology.
[131] Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.
[132] J. Levy,et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids , 2013, Annals of the rheumatic diseases.
[133] Gideon P. Smith,et al. Review of treatment for discoid lupus erythematosus , 2016, Dermatologic therapy.
[134] R. Maciuca,et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) , 2015, Annals of the rheumatic diseases.
[135] L. Jara,et al. Risk factors of systemic lupus erythematosus flares during pregnancy , 2014, Immunologic Research.
[136] L. Arnaud,et al. Late-Onset Systemic Lupus Erythematosus , 2012, Drugs & Aging.
[137] L. Magder,et al. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. , 2012, Arthritis and rheumatism.